Cita Alzheimerwww.cita-alzheimer.org

History of Alzheimer's disease

2015

Start of the prevention trials using anti-amyloid therapy in asymptomatic people with positive biomarkers. A4 study in the United States and start-up of the EPAD project in Europe.

Development of the radiopharmaceutical markers of tau deposits in PET.

Commencement of anti-tau immunotherapy.

Opening of the CITA-alzheimer Foundation's Advanced Therapy and Research Centre's Memory Clinic.

2014

Second visit of the Gipuzkoa Alzheimer Project.

Publication of the diagnostic criteria of the International Working Group (IWG2) based on biomarkers.

Negative results of immunotherapy with bapineuzumab and solanezumab. Possible beneficial effects of solanezumab in milder stages.

Start of prevention trials using anti-amyloid therapies in asymptomatic carriers of pathogenic mutations (DIAN project).

2013

First results of the PGA. First amyloid PET in Gipuzkoa.

First results from the Gipuzkoa Alzheimer Project. Availability of data platform to the scientific community.

Creation of the State Dementia Group by IMSERSO and the Alzheimer's disease State Centre of Reference (CREA) of Salamanca

2012

Failure of the monoclonal antibodies.

Therapeutic trials in pre-clinic AD genetic forms are announced. 

2011

New diagnostic criteria define pre-clinical Alzheimer's and slight deterioration IN Alzheimer's.

Commencement of first AD pre-dementia tests.

Commencement of Gipuzkoa Alzheimer project: more than 500 volunteers.

2010

Failure of gamma-secretase inhibitors.

2009

The European Commission urges its members to put initiatives in place to combat AD.

Creation of CITA Alzheimer.

2008

Failure of Flurizan trial.

2007

P. Maragall announces he is suffering from Alzheimer's disease.

Proposal of the prodomic AD concept.

Failure of Alzhemed trial.

2005

Development of new passive vaccines with monoclonal antibodies.

2004

ADNI Initiative. Amyloid can be seen live, first PET-GDP.

2003

Approval of Memantine.

Commencement of biomarker large-scale genetic study in CSF. 

2002

Failure of the vaccine in humans.

2001

Approval of galantamine.

2000

Approval of rivastigmine.

1999

The vaccine works on a transgenic mouse.

Proposal of Light Cognitive Deterioration concept.

1997

First National Alzheimer's Conference in Pamplona.

1996

Approval of Donepezil.

1995

First mutation described in Presenilins 1 and 2.

First transgenic mouse model.

1994

Ronald Reagan goes public about his diagnosis. 

Foundation of CEAFA.

The World Alzheimer's Day was held on 21 September of this year for the first time.

1993

Identification of the first susceptibility gene: APOE.

The FDA approves the use of Tacrine. 

1991

Foundation of AFAGI.

1987

Identification of the TAU protein and the first determinant gene: APP.

1984

Foundation of Alzheimer's Disease International.

Discovery of beta-amyloid.

1982

Discovery of the acetyl-choline deficit.

1980

Foundation of the Alzheimer's Association.

1970

The disease is recognized as the most common cause of dementia.

1910

Kraepelin mentions "Alzheimer's disease" for the first time.

1906

Alois Alzheimer describes this peculiar disease. 

We use own and third party cookies to improve our services and show related advertising to your preferences by analyzing your browsing habits. If you continue browsing, we consider that you accept the use.
You can change the settings or get more information here.